Elimination of daratumumab interference with IgG antibody titer detection based on the erythrocyte CD38 antigen masking strategy
10.13303/j.cjbt.issn.1004-549x.2026.09.015
- VernacularTitle:基于红细胞CD38抗原遮蔽策略消除达雷妥尤单抗药物对IgG型抗体效价检测的影响
- Author:
Lu LI
1
;
Bin WANG
2
;
Junjie WEI
1
;
Haiyun LIU
1
;
Chuhui YIN
1
;
Weixin WU
1
;
Yinze ZHANG
1
Author Information
1. Shenzhen University General Hospital, Shenzhen 518000, China
2. Shenzhen Futian District Maternity & Child Healthcare Hospital, Shenzhen 518000, China
- Publication Type:Journal Article
- Keywords:
daratumumab (DARA);
antibody titer determination;
indirect antiglobulin test (IAT);
CD38 functional monoclonal antibody
- From:
Chinese Journal of Blood Transfusion
2026;39(9):1269-1272
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To eliminate the interference of daratumumab (DARA) in the titer determination of IgG antiA/antiB antibodies, resolve the discrepancy between test results and theoretical expectations, and obtain accurate and reliable test results. Methods: A group A blood sample with a positive IgG antiA titer result was confirmed to have a recent history of DARA administration. After removal of IgM antibodies from the plasma, IgG antiA/antiB titers were determined using the antiglobulin test card with a serial twofold dilution method, following pretreatment of reagent red blood cells with a rabbit antihuman CD38 functional monoclonal antibody. Results: Without pretreatment with the rabbit antihuman CD38 functional monoclonal antibody, the IgG antiA titer of the sample was 128. After pretreatment, the IgG antiA titer became negative. Conclusion: Based on the red blood cell CD38 antigen masking strategy, pretreatment of red blood cells with a rabbit antihuman CD38 functional monoclonal antibody can eliminate the interference of DARA on the titer determination of IgG antibodies, thereby providing accurate diagnostic evidence and decision support for clinical treatment.
